EFPIA Member Survey on Current Inspection Trends

Recommendation
11-13 November 2025
Vienna, Austria
An advanced Auditor Course with many interactive Sessions and practical Examples
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has been conducting member surveys on inspections since 2003. These are intended to provide an up-to-date overview of the type and scope of GMP inspections carried out at the production sites of member companies. The surveys now also include GDP inspection and ISO certifications. Now the EFPIA has published the "Annual Regulatory GMP/GDP Inspection Survey 2021 Data". Especially with regard to the pandemic, this contains interesting data.
For example, the number of inspections at production sites in 2021 was similar to the number before the pandemic. The trends also triggered by the pandemic continue. Thus, the number of domestic inspections is rising again, while foreign inspections are still low. All types of inspections were carried out (PAI, routine, for cause, etc.) and different inspection tools were used (from purely virtual, to combinations, to completely on-site).
The data suggests that virtual tools such as remote assessments and on-site inspections require a similar inspection duration. However, little consideration was given to the actual time required for preparation on both sides.
But see for yourself: Annual Regulatory GMP/GDP Inspection Survey 2021 Data
Related GMP News
22.10.2025EMA Questions & Answers on Mutual Recognition Agreement (MRA) with US updated
22.10.2025FDA continues to take Root Cause Analysis and CAPA very seriously
14.10.2025Two new GDP Non-Compliance Reports from Romania
01.10.2025Alternative Inspection Methods of the FDA
24.09.2025FDA issues final Guidance on Remote Oversight Tools
24.09.2025Four Warning Letter concerning CAPA and Root Cause Analysis published


